As of Jan 20
| +0.35 / +1.29%|
The 10 analysts offering 12-month price forecasts for Genomic Health Inc have a median target of 32.50, with a high estimate of 39.50 and a low estimate of 27.00. The median estimate represents a +17.84% increase from the last price of 27.58.
The current consensus among 13 polled investment analysts is to Hold stock in Genomic Health Inc. This rating has held steady since January, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.